PFE Jan 2024 50.000 call
| Previous Close | 0.6600 |
| Open | 0.7400 |
| Bid | 0.6200 |
| Ask | 0.6500 |
| Strike | 50.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.6100 - 0.7400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 21.75k |
- Motley Fool
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor. The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.
- Reuters
UPDATE 4-J&J bows out of RSV vaccine race after scrapping trial
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. The drugmaker, which started the global study in 2021 in more than 27,000 adults aged 60 years and older, did not provide any further details about the trial.
- Reuters
UPDATE 3-J&J bows out of RSV vaccine race after scrapping trial
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order to "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. J&J, however, said it plans to share results from the late-stage study with the scientific community.
